{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:00:07Z","timestamp":1786114807179,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970329"],"award-info":[{"award-number":["81970329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2025GH-YBXM-072"],"award-info":[{"award-number":["2025GH-YBXM-072"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119726","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:14:52Z","timestamp":1783170892000},"page":"119726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Protective effects of ACF210, a dual GLP-1\/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D"],"prefix":"10.1016","volume":"201","author":[{"given":"Qingfeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-307X","authenticated-orcid":false,"given":"Qingbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s42255-024-01190-w","article-title":"Diabetes in China: epidemiology, pathophysiology and multi-omics","volume":"7","author":"Jia","year":"2025","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12933-025-02953-9","article-title":"The role of insulin resistance in the longitudinal progression from NAFLD to cardiovascular-kidney-metabolic disease","volume":"24","author":"Hou","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12933-025-02881-8","article-title":"Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk","volume":"24","author":"Zhou","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"Pt 3","key":"10.1016\/j.biopha.2026.119726_bib4","article-title":"Effects of chitosan guanidine on blood glucose regulation and gut microbiota in T2DM","volume":"279","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119726_bib5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biopha.2026.119726_bib6","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.cmet.2024.10.004","article-title":"Hyperglycemia-triggered lipid peroxidation destabilizes STAT4 and impairs anti-viral Th1 responses in type 2 diabetes","volume":"36","author":"Gray","year":"2024","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12875-021-01455-3","article-title":"Therapeutic inertia in proteinuria management among type 2 diabetes (T2DM) patients in primary care settings: prevalence and associated risk factors","volume":"22","author":"Chan","year":"2021","journal-title":"BMC Fam. Pract."},{"key":"10.1016\/j.biopha.2026.119726_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/bs.apcsb.2023.12.017","article-title":"Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: past, present, and future","volume":"142","author":"Das","year":"2024","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.biopha.2026.119726_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.apha.2020.02.001","article-title":"Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: a novel tool to probe GLP-1R pharmacology","volume":"88","author":"Willard","year":"2020","journal-title":"Adv. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119726_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacbts.2023.05.012","article-title":"The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF","volume":"8","author":"Withaar","year":"2023","journal-title":"JACC Basic. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119726_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-642-17214-4_3","article-title":"GLP-1 agonists and dipeptidyl-peptidase IV inhibitors","volume":"203","author":"Gallwitz","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119726_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154272","article-title":"Commentary: Glucose control: not just a bystander in GLP-1RA-mediated cardiovascular protection","volume":"109","author":"Caruso","year":"2020","journal-title":"Metabolism"},{"issue":"15","key":"10.1016\/j.biopha.2026.119726_bib14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119726_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1276488","article-title":"Advances in the study of ELABELA in renal physiological functions and related diseases","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119726_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132898","article-title":"Cardiovascular response to small-molecule APJ activation","volume":"5","author":"Ason","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119726_bib17","article-title":"The role of apelin-APJ system in diabetes and obesity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119726_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170642","article-title":"vitro metabolism of synthetic Elabela\/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA","volume":"145","author":"Nyimanu","year":"2021","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119726_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108822","article-title":"Apelin\/APJ system in inflammation","volume":"109","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119726_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170682","article-title":"Effect of Fc-Elabela-21 on renal ischemia\/reperfusion injury in mice: mediation of anti-apoptotic effect via Akt phosphorylation","volume":"147","author":"Xu","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119726_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115268","article-title":"Therapeutic potential of apelin and Elabela in cardiovascular disease","volume":"166","author":"Gao","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"14","key":"10.1016\/j.biopha.2026.119726_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2174\/1389450123666220826160123","article-title":"Elabela peptide: an emerging target in therapeutics","volume":"23","author":"Sharma","year":"2022","journal-title":"Curr. Drug. Targets"},{"key":"10.1016\/j.biopha.2026.119726_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijcard.2019.06.043","article-title":"Recombinant Elabela-Fc fusion protein has extended plasma half-life and mitigates post-infarct heart dysfunction in rats","volume":"300","author":"Wang","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119726_bib24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/1087057107309035","article-title":"Application of the BD ACTOne technology for the high-throughput screening of Gs-coupled receptor antagonists","volume":"12","author":"Visegrady","year":"2007","journal-title":"J. Biomol. Screen."},{"issue":"10397","key":"10.1016\/j.biopha.2026.119726_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Collaborators","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2026.119726_bib26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1681\/ASN.0000000637","article-title":"Cumulative incidence of mortality associated with cardiovascular-kidney-metabolic (CKM) syndrome","volume":"36","author":"Claudel","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119726_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.biopha.2026.119726_bib28","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.biopha.2026.119726_bib29","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2026.119726_bib30","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc23-0671","article-title":"Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes","volume":"46","author":"Kutz","year":"2023","journal-title":"Diabetes Care"},{"issue":"10193","key":"10.1016\/j.biopha.2026.119726_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2026.119726_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2026.119726_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102076","article-title":"A promising therapeutic peptide and preventive\/diagnostic biomarker for age-related diseases: The Elabela\/Apela\/Toddler peptide","volume":"91","author":"Monastero","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"10","key":"10.1016\/j.biopha.2026.119726_bib34","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.7150\/thno.84308","article-title":"Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation","volume":"13","author":"Xiong","year":"2023","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biopha.2026.119726_bib35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10741-020-09957-5","article-title":"The Elabela-APJ axis: a promising therapeutic target for heart failure","volume":"26","author":"Ma","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2026.119726_bib36","article-title":"Fc-Elabela mitigates heart failure without liver and renal toxicity in mice","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119726_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13574","article-title":"GLP-1 analogs and regional adiposity: a systematic review and meta-analysis","volume":"24","author":"Akoumianakis","year":"2023","journal-title":"Obes. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119726_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tem.2024.07.017","article-title":"The direct targets of metformin in diabetes and beyond","volume":"36","author":"Yao","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2026.119726_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073569","article-title":"Effect of metformin on T2D-induced MAM Ca(2+) uncoupling and contractile dysfunction in an early mouse model of diabetic HFpEF","volume":"23","author":"Dia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119726_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/alr.23546","article-title":"Metformin use reduces the risk of olfactory dysfunction in diabetic patients: a 22-year follow-up study","author":"Chen","year":"2025","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.biopha.2026.119726_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2024.102479","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin","volume":"89","author":"Chan","year":"2024","journal-title":"Tissue Cell."},{"key":"10.1016\/j.biopha.2026.119726_bib42","article-title":"Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic HFpEF model","author":"Mira Hernandez","year":"2024","journal-title":"Cardiovasc. Res."},{"issue":"10431","key":"10.1016\/j.biopha.2026.119726_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2026.119726_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ehjcvp\/pvae027","article-title":"Non-coding RNA therapeutics in the treatment of heart failure","volume":"10","author":"Paterek","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119726_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121546","article-title":"Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: Implications on GLP-1R and cAMP\/PKA signaling pathway in the hippocampus","volume":"320","author":"Darwish","year":"2023","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4093\/dmj.2022.0363","article-title":"Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification","volume":"48","author":"Lee","year":"2024","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"10.1016\/j.biopha.2026.119726_bib47","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jcsm.13025","article-title":"Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis","volume":"13","author":"Kamiya","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib48","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119726_bib49","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1002\/jcp.26339","article-title":"Apelin\/APJ system: a critical regulator of vascular smooth muscle cell","volume":"233","author":"Luo","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119726_bib50","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.drudis.2022.05.004","article-title":"APJ\/apelin: a promising target for the treatment of retinopathy of prematurity","volume":"27","author":"Su","year":"2022","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119726_bib51","article-title":"ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK\/MAPK and PI3K\/AKT signaling pathways","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119726_bib52","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.freeradbiomed.2023.09.030","article-title":"Apelin\/APJ system protects placental trophoblasts from hypoxia-induced oxidative stress through activating PI3K\/Akt signaling pathway in preeclampsia","volume":"208","author":"Ye","year":"2023","journal-title":"Free. Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s13287-020-02063-1","article-title":"ELABELA ameliorates hypoxic\/ischemic-induced bone mesenchymal stem cell apoptosis via alleviation of mitochondrial dysfunction and activation of PI3K\/AKT and ERK1\/2 pathways","volume":"11","author":"Fu","year":"2020","journal-title":"Stem Cell. Res. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119726_bib54","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1111\/dom.15789","article-title":"Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: a comprehensive review and call to action","volume":"26","author":"Czupryniak","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2026.119726_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/10600280241312432","article-title":"Sodium-glucose co-transporter 2 inhibitors and severe urinary tract infections: real-world meta-analysis of cohort studies","author":"Aboukaoud","year":"2025","journal-title":"Ann. Pharmacother."},{"issue":"13","key":"10.1016\/j.biopha.2026.119726_bib56","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119726_bib57","first-page":"1","article-title":"Non-steroidal mineralocorticoid receptor antagonists: a paradigm shift in the management of diabetic nephropathy","author":"Huart","year":"2025","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.biopha.2026.119726_bib58","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119726_bib59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4093\/dmj.2024.0096","article-title":"Enhancing patient outcomes: prioritizing SGLT2is and GLP-1RAs in diabetes with CVD","volume":"48","author":"Koh","year":"2024","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119726_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/14017431.2024.2418086","article-title":"Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials","volume":"58","author":"Kunutsor","year":"2024","journal-title":"Scand. Cardiovasc. J."},{"key":"10.1016\/j.biopha.2026.119726_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2025.106987","article-title":"GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK\/SIRT1 pathway to improve NAFLD","volume":"178","author":"Zhang","year":"2025","journal-title":"Prostaglandins Other Lipid Mediat."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:35:15Z","timestamp":1785965715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S0753332226007626"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119726","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effects of ACF210, a dual GLP-1\/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119726"}}